I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
Millions of people might be on vacation as we hit the dog days, but drug makers and politicians aren’t taking a break from the gamesmanship over high drug prices.
After two... Read more »
Two years after making her first-ever rounds of business meetings at the J.P. Morgan healthcare conference, Alice Zhang has steered her biotech startup, Verge Genomics, into a $32 million Series A... Read more »
Akcea Therapeutics (NASDAQ: AKCA) has beaten rival Alnylam Pharmaceuticals (NASDAQ: ALNY) to a first drug approval, getting the nod for its drug inotersen (Tegsedi) in the European Union.... Read more »
More details from two drug programs up for approval this year to treat a rare genetic disease emerged yesterday, published in side-by-side papers in the New England Journal of Medicine.... Read more »
[Corrected, 7/6/18, 1:26 pm. See below.] Xconomy was dumbstruck this week, and not by the fireworks overhead. Our friend and one of our earliest employees, San Diego editor Bruce... Read more »
Deborah Dunsire, a veteran of Boston’s biotech scene, is taking off. Specifically, she’s taking the top job at Danish pharma firm Lundbeck, according to an announcement this morning.
The move comes... Read more »
Blood tests for cancer, known as liquid biopsies, have become available in recent years to guide treatments for people already diagnosed. But how useful are they?
Global Blood Therapeutics hasn’t finished testing its treatment for sickle cell disease, but the South San Francisco, CA-based company thinks it can get a fast-track approval for the once-a-day pill, voxelotor,... Read more »
Helix, which runs an online outlet for products based on customer DNA, has bought HumanCode, one of the app makers that contributes to its store. Denver-based HumanCode makes BabyGlimpse, which shows... Read more »
Cassandra Trimnell has sickle cell disease. She also loves to travel. For her 30th birthday last year, she and her husband planned a trip to Indonesia, and she figured she would... Read more »
Most of the cancer news this week happened at the massive ASCO meeting in Chicago. But not all, as we’ll see in a moment.
Also this week, Biogen and Eisai reported... Read more »
[Corrected 6/4/18, 1:53 a.m. ET. See below.] One year ago, the FDA made biomedical history. A cancer drug, pembrolizumab (Keytruda), was approved to treat tumors with a specific genetic... Read more »
There’s nothing abstract about a 20 percent jump in a company’s stock price. But yeah, that happened to Loxo Oncology when it released data previews for its American Society for Clinical... Read more »
Amid backlash, renowned geneticist Eric Lander, the Broad Institute president and founding director, apologized today for his toast over the weekend to DNA structure co-discoverer James Watson (pictured) on the occasion... Read more »
The founders of CRISPR-Cas9 startup Editas Medicine have gotten a jump on the next version of CRISPR gene editing. Scientists from Harvard University, Massachusetts General Hospital, and the Broad Institute are... Read more »
[Updated 4/26/18, 2:20pm ET. See below.] The gene-editing technology CRISPR-Cas9 has captured the world’s attention with the possibility of fixing tough diseases and altering human traits. While experimental medicine,... Read more »
Epizyme (NASDAQ: EPZM) said Monday that a pediatric patient taking its experimental cancer drug tazemetostat developed a new cancer, different than the one tazemetostat had been treating. The secondary cancer,... Read more »
The biggest news this week was in oncology, hands down. Merck showed that its immunotherapy pembrolizumab (Keytruda) might become a common option for many patients newly diagnosed with advanced lung cancer,... Read more »
September 5, 2018
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.